Valbiotis (XPAR:ALVAL) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


XPAR:ALVAL Valbiotis SA XPAR:ALVAL
55 GF Score
Price €0.75
GF Value €1.49
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Valbiotis Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Valbiotis's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XPAR:ALVAL vs KHC, GIS: Margin of Safety % (DCF Earnings Based) Comparison

For the Packaged Foods subindustry, Valbiotis's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valbiotis Margin of Safety % (DCF Earnings Based) vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Valbiotis's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Valbiotis's Margin of Safety % (DCF Earnings Based) falls into.


XPAR:ALVAL
55GF Score
Valbiotis SA XPAR:ALVAL
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?

Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued. The current stock price of €0.75 is trading 50% below its estimated GF Value™ of €1.49. GuruFocus considers Valbiotis to be Possible Value Trap.

Key valuation signals for XPAR:ALVAL:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €1.49 vs. price of €0.75 (50% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valbiotis Business Description

Other Exchanges 8JD:Germany
Address 12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
55GF Score

Get the complete analysis for XPAR:ALVAL

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price
€1.49
GF Value